Hiperaldosteronismo primario

  1. Marta Araujo Castro 1
  2. Eider Pascual Corrales 1
  3. Andrés Ortiz Flores 1
  4. Héctor Francisco Escobar Morreale 2
  1. 1 Servicio de Endocrinología y Nutrición, Hospital Universitario Ramón y Cajal e Instituto Ramón y Cajal de Investigación Biomédica (IRYCIS), Madrid, España
  2. 2 Servicio de Endocrinología y Nutrición, Hospital Universitario Ramón y Cajal e Instituto Ramón y Cajal de Investigación Biomédica (IRYCIS), Madrid, España. Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, España. Facultad de Medicina, Universidad de Alcalá, Alcalá de Henares, Madrid, España
Zeitschrift:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Datum der Publikation: 2024

Titel der Ausgabe: Enfermedades endocrinológicas y metabólicas (I) Patología suprarrenal

Serie: 14

Nummer: 13

Seiten: 727-737

Art: Artikel

DOI: 10.1016/J.MED.2024.06.012 DIALNET GOOGLE SCHOLAR

Andere Publikationen in: Medicine: Programa de Formación Médica Continuada Acreditado

Zusammenfassung

Primary hyperaldosteronism (PHA) is the most frequent cause of secondary hypertension (HT). Furthermore, it is associated with greater cardiometabolic and mortality risk than the observed in patients with essential HT. It is recommended to screen for PHA by determining the aldosterone-to-renin ratio in patients with severe and/or resistant HT, HT with hypokalemia, HT and adrenal incidentaloma, HT and a first-degree family history of PHA, and in HT associated with atrial fibrillation that cannot be explained by other causes. If a pathological aldosterone-to-renin ratio is confirmed, dynamic tests should be performed to establish a confirmatory diagnosis; these are usually a saline infusion test or captopril challenge test. These tests can be omitted in patients with overt PHA (plasma aldosterone greater than 20 ng/dl, suppressed renin, and hypokalemia). The last step in the diagnosis is the localization study, being the computed tomography (CT) scan of the adrenal glands the initial test of choice. Nevertheless, in most patients in whom adrenal surgery is considered, adrenal vein sampling (AVS) will be necessary to establish PHA laterality. AVS is not considered necessary in cases of suspected aldosterone-producing adrenocortical carcinoma and/or PHA in patients younger than 35 years with a clear unilateral lesion on a CT/magnetic resonance imaging (MRI) test. The treatment of PHA depends on the results of the localization study: the treatment of choice is a unilateral adrenalectomy in unilateral forms and mineralocorticoid receptor antagonists in bilateral forms.

Bibliographische Referenzen

  • 1. N.K. Hollenberg Aldosterone in the development and progression of renal injury Kidney Int. (2004)
  • 2. M. Araujo-Castro Treatment of primary hyperaldosteronism Med Clin (Barc). (2020)
  • 3. S. Monticone et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice J Am Coll Cardiol. (2017)
  • 4. P. Milliez et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism J Am Coll Cardiol. (2005)
  • 5. J. Yu et al. A Prospective observational study of factors affecting the change in quality of life in patients with primary aldosteronism after treatment Endocr Pract. (2024)
  • 6. M. Araujo-Castro et al. Diagnosis of primary hyperaldosteronism Med Clin (Barc). (2022)
  • 7. S. Monticone et al. Adrenal vein sampling in primary aldosteronism: towards a standardised protocol Lancet Diabetes Endocrinol. (2015)
  • 8. J.J. Siracuse et al. The vascular surgeon's experience with adrenal venous sampling for the diagnosis of primary hyperaldosteronism Ann Vasc Surg. (2014)
  • 9. M. Araujo-Castro et al. Primary aldosteronism: Practical recommendations for treatment and follow-up Hipertens Riesgo Vasc. (2023)
  • 10. Y. Zhou et al. Hypertension outcomes of adrenalectomy in patients with primary aldosteronism: a systematic review and meta-analysis BMC Endocr Disord. (2017)
  • 11. T.A. Williams et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort Lancet Diabetes Endocrinol (2017)
  • 12. M. Araujo-Castro et al. Familial forms and molecular profile of primary hyperaldosteronism Hipertens y Riesgo Vasc. (2022)
  • 13. A. Vaidya et al. The expanding spectrum of primary aldosteronism: Implications for diagnosis, pathogenesis, and treatment Endocr Rev. (2018)
  • 14. J.W. Funder et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline J Clin Endocrinol Metab. (2016)
  • 15. Y. Ohno et al. Adrenal venous sampling-guided adrenalectomy rates in primary aldosteronism: Results of an International Cohort (AVSTAT) J Clin Endocrinol Metab. (2021)
  • 16. O. Mete et al. Overview of the 2022 WHO Classification of Adrenal Cortical Tumors Endocr Pathol. (2022)
  • 17. J.W. Conn I. Painting background. II. Primary aldosteronism, a new clinical syndrome J Lab Clin Med (1955)
  • 18. S.C. Käyser et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: A systematic review and meta-regression analysis J Clin Endocrinol Metab. (2016)
  • 19. J.W. Funder et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline J Clin Endocrinol Metab. (2008)
  • 20. S.C. Käyser et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: A systematic review and meta-regression analysis J Clin Endocrinol Metab. (2016)
Fuente de los datos: Dialnet